.jpg)
.png)
In this issue of Lipid Spin, several articles and a tear sheet focus on the importance of the physical exam in the evaluation of the patient with lipid disorders. While the physical examination remains the cornerstone of patient evaluation and ongoing treatment, all too often those of us in a teaching role find this a rapidly disappearing art.
Article By:
President-elect, Northeast Lipid Association
Preventive CV Medicine, Lipidology and Hypertension
Clinical Assistant Professor of Medicine
NYU Medical School and Center for CV Prevention
New York, NY
Diplomate, American Board of Clinical Lipidology
Each of us should strive "to rise above the routines of the daily ward round and to see in every patient an opportunity not only to serve mankind in the best tradition of medical excellence, but to add to the store of medical knowledge."
–A. McGehee Harvey (1973)
Article By:
CardioTexas, St. David’s Medical Center
Austin, TX
Diplomate, Accreditation Council for Clinical Lipidology
Thank you for the honor of being able to serve as your next President of the NLA. The 2013–2014 program year will be an exciting time, and I look forward to working with our Board of Directors in the continued growth of our organization to meet the educational and scientific needs of you and your patients.
Article By:
National Lipid Association President
Professor of Pharmacy Practice
Oregon State University/Oregon Health and Science University
Portland, OR
Diplomate, Accreditation Council for Clinical Lipidology
The National Lipid Association (NLA) has named Matthew Ito, PharmD (’86), as its new president. Membership of the NLA includes physicians, pharmacists, researchers, nurses, physician assistants and dietitians.
USC School of Pharmacy News – June 2013
Nanette K. Wenger, MD, professor of medicine in the division of cardiology at the Emory University School of Medicine, has been chosen as the recipient of the 2013 National Lipid Association (NLA) Honorary Lifetime Member Award.
Emory News - June 24, 2013
(LAS VEGAS, NV) - The National Lipid Association (NLA) installed Matthew K. Ito, PharmD, FCCP, CLS, FNLA, as President at its Annual Scientific Sessions on May 29, 2013. Dr. Ito is Professor of Pharmacy Practice and Director of the Cardiovascular Pharmacodynamics Laboratory at Oregon State University/Oregon Health & Science University, and was a founding member of the Pacific Lipid Association (PLA). Dr. Ito served as the PLA President from 2009-2010.
NLA Recognizes Several Renowned Lipidologists with Lifetime Member Awards at Annual Sessions Award Ceremony
On Friday, May 3, the U.S. FDA approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. For more information, please click here to read the announcement by Merck & Co.
On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG =200 mg/dL and < 500 mg/dL) with mixed dyslipidemia.
The FDA's review of Vascepa is expected to be completed by December 20, 2013.
The USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co., recently was honored with finalist designation for two major industry awards, the PRSA National Silver Anvil and the PRSA Big Apple Awards.